<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Matrix Metalloproteinase-9 (MMP-9) and Myeloperoxidase (MPO) Levels in Patients with Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/matrix-metalloproteinase-9-mmp-9-and-myeloperoxidase-mpo-levels-in-patients-with-nonobstructive/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/matrix-metalloproteinase-9-mmp-9-and-myeloperoxidase-mpo-levels-in-patients-with-nonobstructive/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2012-12-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Matrix Metalloproteinase-9 (MMP-9) and Myeloperoxidase (MPO) Levels in Patients with Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2012-12-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Matrix Metalloproteinase-9 (MMP-9) and Myeloperoxidase (MPO) Levels in Patients with Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/matrix-metalloproteinase-9-mmp-9-and-myeloperoxidase-mpo-levels-in-patients-with-nonobstructive/"},"url":"https://clinicaltree.github.io/posts/matrix-metalloproteinase-9-mmp-9-and-myeloperoxidase-mpo-levels-in-patients-with-nonobstructive/"}</script><title>Matrix Metalloproteinase-9 (MMP-9) and Myeloperoxidase (MPO) Levels in Patients with Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Matrix Metalloproteinase-9 (MMP-9) and Myeloperoxidase (MPO) Levels in Patients with Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Matrix Metalloproteinase-9 (MMP-9) and Myeloperoxidase (MPO) Levels in Patients with Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1356973200" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Dec 31, 2012 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Zhi-hui Hou MD</a> </em>, <em> <a href="">Bin Lu MD</a> </em>, <em> <a href="">Yang Gao MD</a> </em>, <em> <a href="">Hui-li Cao MD</a> </em>, <em> <a href="">Fang-fang Yu MD</a> </em>, <em> <a href="">Na Jing MD</a> </em>, <em> <a href="">Xi Chen MD</a> </em>, <em> <a href="">Xiang-feng Cong MD</a> </em>, <em> <a href="">Sion K. Roy MD</a> </em>, <em> <a href="">Matthew J. Budoff MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1822 words"> <em>10 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The aim of this study was to evaluate whether matrix metalloproteinase–9 (MMP-9) and myeloperoxidase (MPO) are elevated in patients with nonobstructive coronary artery disease.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Eighty-four patients with nonobstructive coronary artery disease (group A) and 90 patients with no coronary plaques (group B) were enrolled. MMP-9 and MPO levels were compared between the two groups. The relationships between these biomarkers and Framingham risk score were analyzed. Receiver-operating characteristic curves were used to evaluate the ability of these biomarkers to predict the presence of coronary artery plaques.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The MMP-9 and MPO values in group A were significantly higher than in group B ( <em>P</em> &lt; .001). The levels of MMP-9 and MPO showed significant correlations with Framingham risk score ( <em>r</em> = 0.796, <em>P</em> &lt; .001, and <em>r</em> = 0.409, <em>P</em> &lt; .001, respectively). The areas under the receiver-operating characteristic curves for MMP-9 and MPO were 0.80 (95% confidence interval, 0.74–0.87) and 0.74 (95% confidence interval, 0.66–0.81), respectively.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Levels of MMP-9 and MPO are positively correlated with Framingham risk score. Additionally, in patients with nonobstructive coronary artery disease, elevated levels of MMP-9 and MPO may identify patients at risk for future myocardial infarction or sudden cardiac death.</p><p>Early reports have revealed that obstructive coronary artery disease (CAD), as identified by coronary computed tomographic angiography (cCTA) and defined by coronary plaques causing ≥50% reductions in luminal diameter, is valuable for the prognosis of individuals at risk for major adverse cardiovascular events . Nevertheless, individuals undergoing cCTA commonly exhibit nonobstructive plaques. Prior invasive ultrasound and autopsy studies have implicated nonobstructive plaques as central to the pathophysiologic processes of sudden cardiac death and myocardial infarction . But percutaneous or surgical revascularization is performed only in patients with &gt;50% luminal stenosis. Nonobstructive plaques cannot be detected by traditional coronary angiography and may be considered normal.</p><p>Matrix metalloproteinases (MMPs), a family of structurally and functionally related zinc endopeptidases, degrade extracellular matrix proteins and have been implicated in connective tissue destruction and remodeling . MMP-9, a significant member of the MMP family, has been found to degrade a wide range of extracellular matrix proteins, including gelatin, type IV collagen, and other basement membrane proteins . Increased levels of MMP-9 have been found in human atherosclerotic plaques involved in plaque rupture . Myeloperoxidase (MPO) is the most abundant component of primary azurophilic granules in neutrophils and is promptly discharged after activation by different agonists . First identified within human atherosclerotic plaques nearly a decade ago, MPO has emerged as an important factor in the development and progression of atherosclerotic disease . In clinical studies conducted in patients with acute coronary syndromes, an elevated level of MPO was associated with an adverse prognosis and the occurrence of major cardiovascular events .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-recruitment"><span class="mr-2">Patient Recruitment</span><a href="#patient-recruitment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="data-acquisition"><span class="mr-2">Data Acquisition</span><a href="#data-acquisition" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-analysis"><span class="mr-2">Image Analysis</span><a href="#image-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="cad-risk-assessment"><span class="mr-2">CAD Risk Assessment</span><a href="#cad-risk-assessment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="biochemical-analysis"><span class="mr-2">Biochemical Analysis</span><a href="#biochemical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Baseline Characteristics of the Two Groups</p><p>Characteristic Group A Group B_P_ Men 64.3% (54) 63.3% (57) .90 Age (y) 52.68 ± 8.69 53.43 ± 11.29 .44 Body mass index (kg/m 2 ) 25.11 ± 3.68 25.18 ± 3.14 .84 Systolic blood pressure (mm Hg) 144 ± 19 140 ± 17 &lt;.001 Diastolic blood pressure (mm Hg) 86 ± 12 84 ± 10 &lt;.001 Total cholesterol (mmol/L) 6.7 ± 1.2 6.3 ± 1.0 &lt;.001 Low-density lipoprotein cholesterol (mmol/L) 4.3 ± 1.0 3.9 ± 1.0 &lt;.001 High-density lipoprotein cholesterol (mmol/L) 1.5 ± 0.3 1.5 ± 0.4 .93 Diabetes mellitus 13.1% (11) 3.3% (3) &lt;.001 Smoking 44.1% (37) 51.1% (46) .351 Framingham risk score Low risk 14.3% (12) 20.0% (18) .319 Intermediate risk 34.5% (29) 43.3% (39) .234 High risk 51.2% (43) 36.7% (33) .038</p><p>Data are expressed as percentage (number) or as mean ± standard deviation.</p><p>Table 2</p><p>Nonobstructive Plaques in Group A Patients</p><p>Location Subjects Percentage Left main coronary artery 0 0 Left anterior descending coronary artery 52 40.6% Proximal 36 28.1% Mid 16 12.5% Distal 0 0 Diagonal branch 0 0 Left circumflex coronary artery 33 25.8% Proximal 20 15.6% Mid 9 7.0% Distal 0 0 Obtuse marginal branch 4 3.2% Right coronary artery 43 33.6% Proximal 30 23.4% Mid 13 10.2% Distal 0 0 Posterior left ventricular branch 0 0 Posterior descending 0 0</p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MatrixMetalloproteinase9MMP9andMyeloperoxidaseMPOLevelsinPatientswithNonobstructiveCoronaryArteryDiseaseDetectedbyCoronaryComputedTomographicAngiography/0_1s20S1076633212003959.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MatrixMetalloproteinase9MMP9andMyeloperoxidaseMPOLevelsinPatientswithNonobstructiveCoronaryArteryDiseaseDetectedbyCoronaryComputedTomographicAngiography/0_1s20S1076633212003959.jpg" alt="Figure 1, Maximum intensity projection (a) and volume-rendering (b) images of a 56-year-old male patient with chest pain. A nonobstructive plaque was found in the proximal left anterior descending coronary artery ( arrow ). In a 54-year-old man, curved planar reformation image shows an obstructive plaque in the right coronary artery (c) . Traditional coronary angiography (d) confirmed the coronary computed tomographic angiographic finding ( arrow )." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 3</p><p>Serum Levels of Biomarkers in the Two Groups</p><p>Biomarker Minimum 25th Percentile Median 75th Percentile Maximum_P_ Matrix metalloproteinase–9 (ng/mL) Group A 206.10 486.30 592.10 802.20 1178.90 &lt;.001 Group B 142.70 270.20 394.30 490.10 655.30 Myeloperoxidase (ng/mL) Group A 511.30 715.50 953.00 1220.70 1750.70 &lt;.001 Group B 181.95 409.60 554.70 811.40 975.80</p><p>Table 4</p><p>Serum Levels of Biomarkers in the Two Groups after Adjustment for FRS</p><p>Biomarker FRS Group A Group B_P_ Matrix metalloproteinase–9 (ng/mL) Low risk 385.20 ± 104.30 152.50 ± 60.40 &lt;.001 Intermediate risk 575.30 ± 198.90 301.20 ± 113.70 &lt;.001 High risk 969.40 ± 287.30 562.10 ± 201.30 &lt;.001 Myeloperoxidase (ng/mL) Low risk 651.10 ± 274.50 288.20 ± 94.30 &lt;.001 Intermediate risk 1102.30 ± 334.30 683.60 ± 234.80 &lt;.001 High risk 1484.40 ± 446.70 884.20 ± 301.60 &lt;.001</p><p>FRS, Framingham risk score.</p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MatrixMetalloproteinase9MMP9andMyeloperoxidaseMPOLevelsinPatientswithNonobstructiveCoronaryArteryDiseaseDetectedbyCoronaryComputedTomographicAngiography/1_1s20S1076633212003959.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MatrixMetalloproteinase9MMP9andMyeloperoxidaseMPOLevelsinPatientswithNonobstructiveCoronaryArteryDiseaseDetectedbyCoronaryComputedTomographicAngiography/1_1s20S1076633212003959.jpg" alt="Figure 2, Comparison of matrix metalloproteinase–9 (MMP-9) (a) and myeloperoxidase (MPO) (b) levels between the two groups. The serum levels of MMP-9 and MPO in group A were significantly higher than in group B." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MatrixMetalloproteinase9MMP9andMyeloperoxidaseMPOLevelsinPatientswithNonobstructiveCoronaryArteryDiseaseDetectedbyCoronaryComputedTomographicAngiography/2_1s20S1076633212003959.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MatrixMetalloproteinase9MMP9andMyeloperoxidaseMPOLevelsinPatientswithNonobstructiveCoronaryArteryDiseaseDetectedbyCoronaryComputedTomographicAngiography/2_1s20S1076633212003959.jpg" alt="Figure 3, Matrix metalloproteinase–9 (MMP-9) (a) and myeloperoxidase (MPO) (b) levels. The serum levels of MMP-9 and MPO showed significant correlations with Framingham risk score (FRS) ( r = 0.796, P &lt; .001, and r = 0.409, P &lt; .001, respectively)." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MatrixMetalloproteinase9MMP9andMyeloperoxidaseMPOLevelsinPatientswithNonobstructiveCoronaryArteryDiseaseDetectedbyCoronaryComputedTomographicAngiography/3_1s20S1076633212003959.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/MatrixMetalloproteinase9MMP9andMyeloperoxidaseMPOLevelsinPatientswithNonobstructiveCoronaryArteryDiseaseDetectedbyCoronaryComputedTomographicAngiography/3_1s20S1076633212003959.jpg" alt="Figure 4, The areas under the receiver-operating characteristic curves for matrix metalloproteinase–9 (MMP-9), myeloperoxidase (MPO), and the Framingham risk score (FRS) were 0.80 (95% confidence interval [CI], 0.74–0.87), 0.74 (95% CI, 0.66–0.81), and 0.66 (95% CI, 0.58–0.75), respectively. The performance of MMP-9 to predict plaques was significantly better than that of FRS ( z = 2.60, P &lt; .01). No significant difference was found in the performance of MPO and FRS to predict plaque ( z = 1.32, P &gt; .05)." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusions-1"><span class="mr-2">Conclusions</span><a href="#conclusions-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="acknowledgments"><span class="mr-2">Acknowledgments</span><a href="#acknowledgments" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Matsumoto N., Sato Y., Yoda S., et. al.: Prognostic value of nonobstructive CT low-dense coronary artery plaques detected by multislice computed tomography. Circ J 2007; 71: pp. 1898-1903.</p><li><p>2. Min J.K., Lin F.Y., Dunning A.M., et. al.: Incremental prognostic significance of left ventricular dysfunction to coronary artery disease detection by 64-detector row coronary computed tomographic angiography for the prediction of all-cause mortality: results from a two centre study of 5330 patients. Eur Heart J 2010; 31: pp. 1212-1219.</p><li><p>3. Virmani R., Burke A.P., Farb A., et. al.: Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47: pp. C13-C18.</p><li><p>4. Ehara S., Kobayashi Y., Yoshiyama M., et. al.: Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 2004; 110: pp. 3424-3429.</p><li><p>5. Visse R., Nagase H.: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: pp. 827-839.</p><li><p>6. Newby A.C.: Dual role of matrix metalloproteinases (matrixes) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85: pp. 1-31.</p><li><p>7. Brown D.L., Hibbs M.S., Kearney M., et. al.: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: pp. 2125-2131.</p><li><p>8. Arnhord J.: Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc) 2004; 69: pp. 4-9.</p><li><p>9. Daugherty A., Dunn J.L., Rateri D.L., et. al.: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: pp. 437-444.</p><li><p>10. Brennan M.L., Penn M.S., Van Lente F., et. al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: pp. 1595-1604.</p><li><p>11. Lin Fay Y., Shaw Leslee J., Dunning Allison M., et. al.: Mortality risk in symptomatic patients with nonobstructive coronary artery disease. J Am Coll Cardiol 2011; 58: pp. 510-519.</p><li><p>12. Cheng V.Y., Wolak A., Gutstein A., et. al.: Low-density lipoprotein and noncalcified coronary plaque composition in patients with newly diagnosed coronary artery disease on computed tomographic angiography. Am J Cardiol 2010; 105: pp. 761-766.</p><li><p>13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults : Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: pp. 2486-2497.</p><li><p>14. Ambrose J.A., Tannenbaum M.A., Alexopoulos D., et. al.: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: pp. 56-62.</p><li><p>15. Corrales-Medina V.F., Madjid M., Musher D.M.: Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010; 10: pp. 83-92.</p><li><p>16. Muller J.E., Tawakol A., Kathiresan S., et. al.: New opportunities for identification and reduction of coronary risk: treatment of vulnerable patients, arteries, and plaques. J Am Coll Cardiol 2006; 47: pp. C2-C6.</p><li><p>17. Luttun A., Lutgens E., Manderveld A., et. al.: Loss of matrix metalloproteinase-9 or matrixmetalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004; 109: pp. 1408-1414.</p><li><p>18. Loftus I.M., Naylor A.R., Goodall S., et. al.: Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000; 31: pp. 40-47.</p><li><p>19. Hazen S.L.: Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 2004; 24: pp. 1143-1146.</p><li><p>20. Sugiyama S., Okada Y., Sukhova G.K., et. al.: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating-factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: pp. 879-891.</p><li><p>21. Fu X., Kassim S.Y., Parks W.C., et. al.: Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001; 276: pp. 41279-41287.</p><li><p>22. Falk E., Shah P.K., Fuster V.: Coronary plaque disruption. Circulation 1995; 92: pp. 657-671.</p><li><p>23. Derosa G., D’Angelo A., Ciccarelli L., et. al.: Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: pp. 227-231.</p><li><p>24. Tayebjee M.H., Nadar S., Blann A.D., et. al.: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo- Scandinavian Cardiac Outcomes Trial ASCOT. Am J Hypertens 2004; 17: pp. 764-769.</p><li><p>25. Sundstrom J., Evans J.C., Benjamin E.J., et. al.: Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109: pp. 2850-2856.</p><li><p>26. Noji Y., Kajinami K., Kawashiri M.A., et. al.: Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39: pp. 380-384.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-20/'>Volume 20</a>, <a href='/categories/issue-1/'>Issue 1</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Matrix%20Metalloproteinase-9%20(MMP-9)%20and%20Myeloperoxidase%20(MPO)%20Levels%20in%20Patients%20with%20Nonobstructive%20Coronary%20Artery%20Disease%20Detected%20by%20Coronary%20Computed%20Tomographic%20Angiography%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fmatrix-metalloproteinase-9-mmp-9-and-myeloperoxidase-mpo-levels-in-patients-with-nonobstructive%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Matrix%20Metalloproteinase-9%20(MMP-9)%20and%20Myeloperoxidase%20(MPO)%20Levels%20in%20Patients%20with%20Nonobstructive%20Coronary%20Artery%20Disease%20Detected%20by%20Coronary%20Computed%20Tomographic%20Angiography%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fmatrix-metalloproteinase-9-mmp-9-and-myeloperoxidase-mpo-levels-in-patients-with-nonobstructive%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fmatrix-metalloproteinase-9-mmp-9-and-myeloperoxidase-mpo-levels-in-patients-with-nonobstructive%2F&text=Matrix%20Metalloproteinase-9%20(MMP-9)%20and%20Myeloperoxidase%20(MPO)%20Levels%20in%20Patients%20with%20Nonobstructive%20Coronary%20Artery%20Disease%20Detected%20by%20Coronary%20Computed%20Tomographic%20Angiography%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/after-hours-coverage-of-various-radiologic-subspecialties-and-its-impact-on-the-fourth-year-radiolog/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>After-hours Coverage of Various Radiologic Subspecialties and Its Impact on the Fourth-year Radiology Residency Curriculum</h3><div class="text-muted small"><p> Rationale and Objective The modification of the initial radiology board exam series has as a concerted aim the promotion of subspecialization. Yet, in practice, fellowship-trained radiologists may...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-semi-automatic-volumetric-vx2-hepatic-tumor-segmentation-from-cone-beam-ct-and-multi-d/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of Semi-automatic Volumetric VX2 Hepatic Tumor Segmentation from Cone Beam CT and Multi-detector CT with Histology in Rabbit Models</h3><div class="text-muted small"><p> Rationale and Objectives The purpose of this study was to compare tumor volume in a VX2 rabbit model as calculated using semiautomatic tumor segmentation from C-arm cone-beam computed tomography (...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-t1-dgemric-and-quantitative-t2-mri-in-preoperative-acl-rupture-patients/"><div class="card-body"> <em class="small" data-ts="1356973200" data-df="ll" > Dec 31, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of T1ρ, dGEMRIC, and Quantitative T2 MRI in Preoperative ACL Rupture Patients</h3><div class="text-muted small"><p> Rationale and Objectives T1ρ, inversion recovery sequence with a gadolinium contrast agent (dGEMRIC), and T2 mapping have shown sensitivity toward different osteoarthritic-associated compositional...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/in-vivo-endoluminal-ultrasound-biomicroscopic-imaging-in-a-mouse-model-of-colorectal-cancer/" class="btn btn-outline-primary" prompt="Older"><p>In Vivo Endoluminal Ultrasound Biomicroscopic Imaging in a Mouse Model of Colorectal Cancer</p></a> <a href="/posts/optimizing-adjuvant-treatment-decisions-for-stage-t2-rectal-cancer-based-on-mesorectal-node-size/" class="btn btn-outline-primary" prompt="Newer"><p>Optimizing Adjuvant Treatment Decisions for Stage T2 Rectal Cancer Based on Mesorectal Node Size</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
